Sign in to view content

Interim Results of the Phase 1-2 PRISM Trial Evaluating 4D-150 a Dual-Transgene Intravitreal Genetic Medicine for Neovascular (Wet) Age-Related Macular Degeneration

Christine Kay, MD

Video
Published 2023

Related

Real-world U.S. outcomes of anti-VEGF therapy in diabetic macular edema
Thomas A. Ciulla, MD, MBA, FASRS
Updates from the Field
2017
Predictors of As-Needed Ranibizumab Injection Frequency in Patients With Macular Edema Following Retinal Vein Occlusion
Glenn C. Yiu, MD, PhD
Annual Meeting Talks
2021
One Year and Beyond: Results of Phase 1b Study of KSI-301, an AntiVEGF Antibody Biopolymer Conjugate With Extended Durability, in wAMD, DME, and RVO
Mark R. Barakat, MD
Updates from the Field
2020

Category: AMD-Neovascular

See more